Obatoclax, a first-generation pan-Bcl-2 family antagonist (putative BH3 mimetics) was assessed in phase I/II study in patients older than 70 years with treatment naive AML (Schimmer et al, 2014). Here, BCL2 is linked to acute myeloid leukemia.